IMC Chicago’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.9M Sell
20,300
-2,800
-12% -$1.43M ﹤0.01% 1482
2026
Q1
$12.1M Buy
23,100
+6,300
+38% +$3.01M ﹤0.01% 1134
2025
Q4
$9.78M Buy
+16,800
New +$8.58M ﹤0.01% 1240
2023
Q2
Sell
-11,500
Closed -$2.79M 1356
2023
Q1
$2.79M Sell
11,500
-19,300
-63% -$5.26M ﹤0.01% 762
2022
Q4
$8.94M Buy
+30,800
New +$3.01M 0.01% 475

Other funds holding MDGL

IMC Chicago's MDGL Position: Q2 2026 in Review

IMC Chicago increased its Madrigal Pharmaceuticals (MDGL) stake by 39% in Q2 2026, buying an estimated $1.56M and bringing the position to 10,847 shares worth $5.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

IMC Chicago first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.02M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • IMC Chicago held 10,847 shares of Madrigal Pharmaceuticals worth $5.82M as of Q2 2026.
  • IMC Chicago bought 3,052 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.56M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #1976 holding.
  • IMC Chicago first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • IMC Chicago's Madrigal Pharmaceuticals position peaked at $7.02M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.